Statements Of Operations And Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenue:
Licensing fees	$ 730,635	$ 479,317	$ 149,196
Peptide and consumer product sales	679,907	309,379	221,876
Consumer product sales to affiliated company	480,796	62,987	0
Administrative services revenue, related party	0	0	20,196
Total revenue	1,891,338	851,683	391,268
Cost of revenue:
Cost of peptide and consumer product sales	482,033	219,504	176,720
Cost of consumer product sales to affiliated company	251,274	40,990	0
Cost of administrative services revenue, related party	0	0	19,800
Total cost of revenue	733,307	260,494	196,520
Gross profit	1,158,031	591,189	194,748
Operating expenses:
Research and development	501,044	748,663	722,523
Marketing and business development	937,508	622,846	506,742
General and administrative	1,417,467	1,530,333	1,473,352
Accounting, legal and professional fees	597,160	531,726	579,443
Depreciation and amortization	109,175	113,777	130,596
Total operating expenses	3,562,354	3,547,345	3,412,656
Loss from operations	(2,404,323)	(2,956,156)	(3,217,908)
Other income (expense):
Interest income	3,728	3,074	9,649
Interest expense on convertible notes payable	0	(138,979)	(96,897)
Interest expense on convertible note payable, related party	0	(534,465)	(388,625)
Accretion of discount on convertible notes payable	0	(73,468)	(32,094)
Accretion of discount on convertible notes payable, related party	0	(141,440)	(49,160)
Debt conversion inducement expense	0	(3,806,966)	0
Gain from sale of assets	6,000	0	0
Equity in loss of affiliated company	(85,686)	(65,601)	0
Change in value of option to purchase interest in affiliated company	(8,295)	3,199	0
Other income (expense), net	(84,253)	(4,754,646)	(557,127)
Net loss and comprehensive loss	$ (2,488,576)	$ (7,710,802)	$ (3,775,035)
Basic and diluted net loss per share	$ (0.05)	$ (0.28)	$ (0.15)
Weighted average shares outstanding	49,720,255	27,124,159	25,653,512